<DOC>
	<DOCNO>NCT00002990</DOCNO>
	<brief_summary>RATIONALE : Biological therapy BCG use different way stimulate immune system stop cancer cell grow . PURPOSE : This randomized phase III trial study four different regimen BCG compare well work treat patient undergone surgery bladder cancer .</brief_summary>
	<brief_title>Surgery BCG Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Demonstrate complete transurethral resection papillary tumor , one third dose BCG ( Bacillus Calmette-Guerin vaccine ; OncoTICE ) equivalent full dose BCG short term maintenance equivalent long term maintenance respect duration disease free interval , recurrence rate , percentage patient increase T-category great T1 , incidence carcinoma situ follow-up . - Demonstrate one third dose BCG short term maintenance associate few local systemic side effect . OUTLINE : This prospective randomized study . At 7-15 day transurethral resection , patient begin receive one follow four regimen : - Regimen 1 : One third dose Bacillus Calmette-Guerin ( BCG ) vaccine plus short term maintenance . Patients receive one third dose BCG instill week 6 week , follow three weekly instillation month 3 , 6 , 12 . - Regimen 2 : Full dose BCG plus short term maintenance . Patients receive full dose BCG instill week 6 week , follow three weekly instillation month 3 , 6 , 12 . - Regimen 3 : One third dose BCG plus long term maintenance . Patients receive one third dose BCG instill week 6 week , follow three weekly instillation month 3 , 6 , 12 , 18 , 24 , 30 36 . - Regimen 4 : Full dose BCG plus long term maintenance . Patients receive full dose BCG instill week 6 week , follow three weekly instillation month 3 , 6 , 12 , 18 , 24 , 30 , 36 . The patient follow every 3 month first 3 year , every 6 month thereafter . PROJECTED ACCRUAL : 1288 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma bladder follow type : Multiple ( great 10 ) , resectable , T1 Ta , grade G1G3 Solitary T1 GIII tumor PATIENT CHARACTERISTICS : Age : 85 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Values use evaluate function may exceed two time upper limit normal Renal : Values use evaluate function may exceed two time upper limit normal Other : No second malignancy except basal cell skin carcinoma Not pregnant nursing No uncontrollable urinary tract infection No active tuberculosis No HIV antibody No leukemia No Hodgkin 's disease No transplant recipient PRIOR CONCURRENT THERAPY : Biologic therapy : No prior treatment BCG Chemotherapy : No cytostatic agent within past 3 month Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>